Skip to main content
< Back
About
About the conference
App
Organisers & Partners
Latest updates
Press room
Registration
Venue 22
About the venue
Rooms
Call for abstracts
Programme 22
Tracks 22
Speakers 22
Side events 22
Subscribe
days
hours
minutes
seconds
Treatment
Sessions
Wednesday, 23 November
09:00
Ensuring adequate pain relief whilst reducing addiction risk: lessons learnt and the way forward
09:00
to
10:30
Main stage
Plenary session
10:50
Addressing substance use and substance use disorders in humanitarian settings: the role of evidence-based prevention, treatment and care
10:50
to
12:20
Insights zone 4 (I4)
Structured session
Drug treatment
10:50
to
12:20
Knowledge market 3 (K3)
Oral presentation session
Emerging changes in Europe's cannabis situation: policy preparedness and responses to a dynamic situation
10:50
to
12:20
Knowledge market 4 (K4)
Structured session
Gambling Research
10:50
to
12:20
Insights zone 3 (I3)
Oral presentation session
Gaming and gambling: Characteristics, harms, correlates, and treatment
10:50
to
12:20
Networking zone 2 (N2)
e-poster guided tour
Reaching out
10:50
to
12:20
Networking zone 4 (N4)
Short communication session
Substance use, mental health and mental well-being: observations, interventions and recovery promotion
10:50
to
12:20
Networking zone 3 (N3)
Short communication session
13:20
Global digital addiction interventions: adaptations to target audiences and effectiveness
13:20
to
14:50
Insights zone 2 (I2)
Structured session
Migration, substance use and interventions in Europe
13:20
to
14:50
Insights zone 4 (I4)
Structured session
Precision Medicine and Novel Approaches to the Treatment Alcohol Use Disorder
13:20
to
14:50
Central square 1 (C1)
Structured session
The future for Digital Addictions Services. An update from the DigitAS-DADE Project
13:20
to
14:50
Central square 2 (C2)
Structured session
15:00
Convergence in behavioural addictions
15:00
to
16:30
Main stage
Structured session
Implementation of quality standards in drug demand reduction – where we are and where we are going?
15:00
to
16:30
Knowledge market 1 (K1)
Structured session
Injecting-related infections and drug surveillance
15:00
to
16:30
Knowledge market 3 (K3)
Oral presentation session
Short communications on alcohol: Covid, Ketamine, Cognition, Consumption
15:00
to
16:30
Networking zone 3 (N3)
Short communication session
Substance use and mental health disorders in Europe: prevalence, models of care, and implementation in a challenging COVID-19 context
15:00
to
16:30
Knowledge market 2 (K2)
Structured session
16:50
Alcohol use disorder treatment and its epidemiology
16:50
to
18:20
Central square 1 (C1)
Oral presentation session
EU4MD Treatment facility survey
16:50
to
18:20
Networking zone 2 (N2)
Oral presentation session
Hepatitis C prevention and treatment among people who inject drugs: Global progress and future requirements
16:50
to
18:20
Knowledge market 3 (K3)
Structured session
Impact and lessons learned in implementing and sustaining Needs-Based Planning models for substance use and mental health services and systems
16:50
to
18:20
Knowledge market 2 (K2)
Structured session
Treatment options for drug users in prisons in Central Asia and Germany
16:50
to
18:20
Networking zone 1 (N1)
Structured session
Why we need evidence-based approaches for the universal measurement of cannabis: rationale and implications for public health, treatment and research
16:50
to
18:20
Main stage
Structured session
18:30
Psychedelic-assisted treatment for substance use disorders – long overlooked or now overhyped?
18:30
to
19:30
Main stage
Big debate
Thursday, 24 November
09:00
Re-imagine recovery
09:00
to
10:30
Main stage
Plenary session
The Spanish Network on Research on Primary Attention on Addiction (RIAPAd): a new multilevel integrated model of responsible research on Addiction Disorders
09:00
to
10:30
Knowledge market 4 (K4)
Structured session
10:50
Alcohol and AUD during the life-cycle
10:50
to
12:20
Networking zone 3 (N3)
Short communication session
From Harm to Risk Reduction: OKANA’s 360o approach in Athens
10:50
to
12:20
Knowledge market 4 (K4)
Structured session
Neurology and neuropsychology
10:50
to
12:20
Central square 3 (C3)
Oral presentation session
Substance use and trauma
10:50
to
12:20
Knowledge market 2 (K2)
Oral presentation session
Understanding women's drug use, responses and recovery
10:50
to
12:20
Networking zone 4 (N4)
Short communication session
13:20
Behavioral addictions: Diverse populations, challenges, and solutions
13:20
to
14:50
Networking zone 1 (N1)
e-poster guided tour
Diversity, stigma, and vulnerability
13:20
to
14:50
Networking zone 4 (N4)
Short communication session
Hepatitis C testing and treatment
13:20
to
14:50
Knowledge market 3 (K3)
Oral presentation session
Novel approaches of alcohol use disorder
13:20
to
14:50
Central square 1 (C1)
Oral presentation session
Smoking and e-cigarettes
13:20
to
14:50
Central square 3 (C3)
Oral presentation session
Uppers, downers and psychedelics
13:20
to
14:50
Networking zone 3 (N3)
Short communication session
15:00
A global symposium on the renaissance and promise of psychedelics for mental and substance use disorder treatment
15:00
to
16:30
Main stage
Structured session
Alcohol epidemiology and interventions
15:00
to
16:30
Networking zone 3 (N3)
Short communication session
Drug and alcohol treatment
15:00
to
16:30
Networking zone 1 (N1)
e-poster guided tour
Drug deaths: A social, structural and systems analysis
15:00
to
16:30
Knowledge market 1 (K1)
Structured session
Implementing Methamphetamine Prevention Strategies into Action (IMPRESA)
15:00
to
16:30
Knowledge market 4 (K4)
Structured session
Models to improve the health of people who inject drugs
15:00
to
16:30
Knowledge market 3 (K3)
Oral presentation session
Prevention, testing and treatment of Hepatitis C and other infections
15:00
to
16:30
Networking zone 4 (N4)
Short communication session
16:50
How to develop global surveys, guidelines, checklists and consensus statements in prevention and treatment of addiction: new innovations in the pandemic era
16:50
to
18:20
Insights zone 4 (I4)
Structured session
Informing and delivering treatment
16:50
to
18:20
Networking zone 3 (N3)
Short communication session
Insights from treatment I
16:50
to
18:20
Central square 3 (C3)
Oral presentation session
Opportunities and challenges for countries in transition to overcome barriers to evidence-based policies and interventions
16:50
to
18:20
Networking zone 2 (N2)
Structured session
Problem gambling: models and their ethical implications
16:50
to
18:20
Insights zone 3 (I3)
Structured session
Treatment for cannabis use disorder: an update focusing in cultural characteristics
16:50
to
18:20
Knowledge market 4 (K4)
Structured session
18:30
Addiction, compulsive behaviours and unhealthy habits - A common aetiology and implications for practice?
18:30
to
19:30
Main stage
Big debate
On the path towards elimination of hepatitis C – Models of care to reach people who inject drugs for testing and treatment
18:30
to
19:30
Knowledge market 4 (K4)
Structured session
Friday, 25 November
09:00
Insights from treatment II
09:00
to
10:30
Central square 2 (C2)
Oral presentation session
10:50
Global Issues - Backcasting exercise
10:50
to
12:20
Insights zone 1 (I1)
InterGLAM cinema
COVID-19-adapted addiction services and impact for service users
10:50
to
12:20
Insights zone 4 (I4)
Structured session
13:20
Barriers in the implementation of harm reduction interventions in European prisons. From evidence to practice
13:20
to
14:50
Main stage
Structured session
New advances in alcohol clinical research: evidence from three large National Institute for Health Research-funded randomised controlled trials
13:20
to
14:50
Networking zone 3 (N3)
Structured session
Working with the most vulnerable
13:20
to
14:50
Central square 3 (C3)
Oral presentation session
15:30
Closing keynote: Providing care in a time of war — perspectives from Ukraine
15:30
to
16:00
Main stage
Plenary session
Presentations
Wednesday, 23 November
09:00
Keynote presentation
EFIC recommendations: When to use opioids for chronic pain and when not to
09:00
to
10:30
Main stage
Winfried Häuser
Keynote presentation
Pain and the opioid overdose crisis in the U.S.: experiences, lessons learned, and the path forward
09:00
to
10:30
Main stage
Christopher M. Jones
Keynote presentation
Changing perspectives on the use of medicines for pain
09:00
to
10:30
Main stage
Cathy Stannard
10:50
Oral presentation
1. Priorities for addressing substance use disorder in humanitarian settings
10:50
to
12:20
Insights zone 4 (I4)
M. Claire Greene
Oral presentation
2. Substance Use Among Populations Displaced by Conflict: Assessments, Findings, Recommendations
10:50
to
12:20
Insights zone 4 (I4)
Nadine Ezard
Oral presentation
5. Addressing substance use and related problems in reception settings in Europe
10:50
to
12:20
Insights zone 4 (I4)
Charlotte De Kock,
Klaudia Palczak
Oral presentation
6. Caregiving packages in conflict and humanitarian settings for prevention of substance use and other health and social consequences and for child protection and development
10:50
to
12:20
Insights zone 4 (I4)
Wadih Maalouf
Oral presentation
7. Understanding and Responding to Substance Use and Abuse in the Palestinian Refugee Camps inLebanon Prior to and During COVID-19 Times
10:50
to
12:20
Insights zone 4 (I4)
Marie Claire Van Hout
Oral presentation
3. Handbook on Addressing Substance Use Disorders in Humanitarian Settings – Access to Services for Displaced Populations and Host Communities in Acute and Protracted Emergencies
10:50
to
12:20
Insights zone 4 (I4)
Anja Busse
Short communication
Drug use, anxiety and depression among people living in prison in Belgium
10:50
to
12:20
Networking zone 3 (N3)
Kim Fernandez
Short communication
The temporal association between frequency of methamphetamine use, depression, and anxiety in a community-recruited cohort of methamphetamine smokers
10:50
to
12:20
Networking zone 3 (N3)
Zoe Duncan
Short communication
Effectiveness of mental health warnings on tobacco packaging in people with and without common mental health conditions: an online randomised experiment
10:50
to
12:20
Networking zone 3 (N3)
Katherine Sawyer
Short communication
A realist evaluation of greenspace programmes for improving mental health and supporting people with problem substance use
10:50
to
12:20
Networking zone 3 (N3)
Wendy Masterton
Short communication
Association between cannabis use and mental health disorders in adolescents in Catalonia: results of a cohort study
10:50
to
12:20
Networking zone 3 (N3)
Regina Muñoz-Galán
Short communication
Physical activity during treatment for substance use disorder: What a systematic review tells us
10:50
to
12:20
Networking zone 3 (N3)
Florence Piché
Oral presentation
A qualitative exploration of patient’s experience of mobile telephone-delivered Contingency Management (mCM) to promote adherence to supervised methadone in UK pharmacies
10:50
to
12:20
Knowledge market 3 (K3)
Carol-Ann Getty
Oral presentation
I don’t chase drugs anymore and I’m not dead': The Impact of Safer Opioid Supply Programs in Ontario Canada on Client’s Health and Drug Use
10:50
to
12:20
Knowledge market 3 (K3)
Rose Schmidt
Oral presentation
Delivering telemedicine to vulnerable people with opioid use disorder: Outcomes of a program co-constructed and implemented with a community-based harm reduction service in Montreal, Canada
10:50
to
12:20
Knowledge market 3 (K3)
Stine Hoj
Oral presentation
Access to their own drugs': Navigating the drawbacks and benefits of injectable hydromorphone and diacetylmorphine treatment in Vancouver, BC
10:50
to
12:20
Knowledge market 3 (K3)
Samara Mayer
Oral presentation
A scoping review on cryptocurrency trading among young people and its association with gambling and mental health
10:50
to
12:20
Insights zone 3 (I3)
Benjamin Johnson
e-poster
Gaming disorder associated to comorbid disorders in an immigrant adolescent: A clinical case study.
10:50
to
12:20
Networking zone 2 (N2)
Carla Andrade
e-poster
The perceived importance of a Therapeutical Contract in a CBT based treatment of problem gamblers
10:50
to
12:20
Networking zone 2 (N2)
Pedro Hubert
e-poster
Gambling in Ireland: profile of cases from an analysis of a national treatment reporting system.
10:50
to
12:20
Networking zone 2 (N2)
Ita Condron
e-poster
At odds with success; identifying and responding to gambling behaviour among irish undergraduate students
10:50
to
12:20
Networking zone 2 (N2)
Emmett Tuite
e-poster
Bet You Can Help: Addressing gambling related harms through a universal public health education approach
10:50
to
12:20
Networking zone 2 (N2)
Neil Platt
e-poster
Industry self-regulation vs legal regulation: lower compliance with loot box probability disclosure requirements in the UK than in China
10:50
to
12:20
Networking zone 2 (N2)
Leon Y. Xiao
e-poster
The relationship between gaming, self-harm, resilience, loneliness, and attachment in adulthood
10:50
to
12:20
Networking zone 2 (N2)
Jaroslava Suchá
Oral presentation
Treatment-seeking problem gamblers: characteristics of individuals who offend to finance gambling
10:50
to
12:20
Insights zone 3 (I3)
Amanda Roberts
e-poster
The Questionnaire of Digital Game Playing (QDGP)
10:50
to
12:20
Networking zone 2 (N2)
Martin Dolejš
Oral presentation
Characterizing habit formation in modern slot machine gambling
10:50
to
12:20
Insights zone 3 (I3)
Luke Clark
e-poster
Gambling Motives and Offshore Gambling: A Finnish Population Study
10:50
to
12:20
Networking zone 2 (N2)
Heli Hagfors
Oral presentation
Cue-reactivity and inhibitory control in behavioral addcitions: an overview of functional neuroimaging studies
10:50
to
12:20
Insights zone 3 (I3)
Kjell Büsche
Short communication
Telegram as a space for peer-leded harm reduction communities and netreach interventions
10:50
to
12:20
Networking zone 4 (N4)
Sara Rolando
Short communication
OurFutures: A suite of universal evidence-based eHealth programs to prevent substance use and mental ill-health among adolescents
10:50
to
12:20
Networking zone 4 (N4)
Lauren Gardner
Short communication
Collaboration between prevention work and law enforcement in a nightlife drug-using setting: a vulnerable encounter?
10:50
to
12:20
Networking zone 4 (N4)
Annemie Coone
Oral presentation
2. Medical use of cannabis and cannabinoids: an overview of evidence
10:50
to
12:20
Knowledge market 4 (K4)
Mafalda Pardal
Short communication
Addressing Adherence and Success Rates of a Digital Self-Help Intervention for Alcohol and Substance Use with Machine Learning
10:50
to
12:20
Networking zone 4 (N4)
Anna Goudriaan
Oral presentation
5. Treatment of cannabis-related problems in Europe: a typology and evidence overview
10:50
to
12:20
Knowledge market 4 (K4)
Daniel Feingold
Short communication
What’s trending? Using social media to engage with hard to reach groups through an online survey
10:50
to
12:20
Networking zone 4 (N4)
Nicki Killeen
Oral presentation
3. Cannabis-related effects and harms: a scientific overview
10:50
to
12:20
Knowledge market 4 (K4)
Jakob Manthey
Short communication
Accessability of mental health services for people with substance use: findings from the SUMHIT project
10:50
to
12:20
Networking zone 4 (N4)
Jürgen Magerman
Oral presentation
4. Harm reduction for cannabis related problems in Europe and beyond
10:50
to
12:20
Knowledge market 4 (K4)
Iciar Indave
Short communication
Drug use and associated factors in Secondary Education in Basque Country
10:50
to
12:20
Networking zone 4 (N4)
Álvaro Moro Inchaurtieta
Short communication
Mental Health and Addiction Prevention for former refugees: We do it together
10:50
to
12:20
Networking zone 3 (N3)
Jannet De Jonge
Short communication
What aspects of a drug checking service are important in a high-cost drug market?
10:50
to
12:20
Networking zone 4 (N4)
Raimondo Bruno
Introduction
1. Setting the scene: recent cannabis policy developments in European countries
10:50
to
12:20
Knowledge market 4 (K4)
Liesbeth Vandam
13:20
Oral presentation
1. Equitable substance use treatment for migrants, refugees and ethnic minorities: An emerging research domain
13:20
to
14:50
Insights zone 4 (I4)
Inês Hasselberg
Oral presentation
2. Substance use disorders in refugee and migrant groups in Sweden: A nationwide cohort study of 1.2 million people
13:20
to
14:50
Insights zone 4 (I4)
Samantha Harris
Oral presentation
5. Services for vulnerable Migrants who use Drugs in the EU (SEMID-EU)
13:20
to
14:50
Insights zone 4 (I4)
Machteld Busz
Discussion
Ways forward: synthetizing priorities in prevalence studies and intervention needs in the EU
13:20
to
14:50
Insights zone 4 (I4)
Charlotte De Kock,
Klaudia Palczak
Oral presentation
3. Smartphone-based addiction prevention for young refugees: results of a feasibility study
13:20
to
14:50
Insights zone 4 (I4)
Lina-Sophia Falkenberg
Oral presentation
4. The Impact of the Russian Invasion of Ukraine on Needle and Syringe Distribution by Harm Reduction Organizations
13:20
to
14:50
Insights zone 4 (I4)
Benjamin Nikitin
Oral presentation
1. ABC-Training: A New Proposition-Based Variety of Cognitive Bias Modification. Theoretical Background and Initial Results.
13:20
to
14:50
Central square 1 (C1)
Reinout W. Wiers
Oral presentation
2. Phenotyping Individuals with Alcohol Use Disorder: Implications for Precision Medicine and Predicting Non-Abstinent Recovery from Alcohol Use Disorder
13:20
to
14:50
Central square 1 (C1)
Katie Witkiewitz
Oral presentation
3. Examining a Brief Measure and Observed Cutoff Scores to Identify Reward and Relief Drinking Profiles: Psychometric Properties and Pharmacotherapy Response
13:20
to
14:50
Central square 1 (C1)
Victoria R. Votaw
Discussion
New Directions in Behavioral and Pharmacological Treatments and Precision Medicine Approaches for Improving Rates of Recovery from Alcohol Use Disorder
13:20
to
14:50
Central square 1 (C1)
Karl Mann
Oral presentation
3. Immersive Virtual Reality in the Assessment and Treatment of Addictive Disorders: Current Status and Future Perspectives
13:20
to
14:50
Central square 2 (C2)
Simon Langener
Oral presentation
4. Routine outcome monitoring and personalized clinical feedback for people in treatment for substance use disorders. A mixed-method adaptation study
13:20
to
14:50
Central square 2 (C2)
Øyvind Kyrre Grindheim
Discussion
Are Digital Health Interventions for Addiction Services more likely to widen or narrow inequalities?
13:20
to
14:50
Central square 2 (C2)
Marica Ferri
Oral presentation
2. Spanish version of CANreduce. Preliminary findings of a self-guided treatment program to reduce cannabis consumption
13:20
to
14:50
Central square 2 (C2)
Joan-Ignasi Mestre-Pintó
Oral presentation
2. Design and Testing of an Aftercare Mobile App for Substance Use Among Young Adults: An Interdisicplinary Approach in Denmark
13:20
to
14:50
Insights zone 2 (I2)
Adriana del Palacio-Gonzalez
Oral presentation
3. A guided digital intervention to reduce cannabis use: the ICan randomized controlled trial in the Netherland
13:20
to
14:50
Insights zone 2 (I2)
Marleen Olthof
Oral presentation
4. Boozebuster: A Mobile Intervention to Promote Low-Risk Drinking Habits in Young Adults –preliminary results
13:20
to
14:50
Insights zone 2 (I2)
Mieke Schulte
Discussion
Experiences with and opinions on (sub-)cultural adaptions and other forms of tailoring of digital addiction interventions to meet specific expectations of the target audience.
13:20
to
14:50
Insights zone 2 (I2)
Matthijs Blankers
Oral presentation
1. Guided smartphone-based treatment for patients in opioid maintenance treatment in Iran -transdiagnostic treatment for substance use and common mental disorders
13:20
to
14:50
Insights zone 2 (I2)
Michael Schaub
Oral presentation
1. Developing a functional taxonomy for Digital Health Interventions in Addiction Services
13:20
to
14:50
Central square 2 (C2)
Joseph Tay Wee Teck
Oral presentation
2. Digital Health Interventions: Petiscos from clinical practice
13:20
to
14:50
Central square 2 (C2)
Roya Vaziri
15:00
Short communication
This Is Something That Changed My Life': A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders
15:00
to
16:30
Networking zone 3 (N3)
Merve Mollaahmetoglu
Short communication
Changes in retrospectively recalled alcohol use and hazardous drinking pre, during, and post an alcohol sales prohibition in Botswana during COVID pandemic.
15:00
to
16:30
Networking zone 3 (N3)
J. Maphisa Maphisa
Short communication
Exploring the potential for Managed Alcohol Programmes during the COVID-19 pandemic in Scotland: Findings from a mixed methods study
15:00
to
16:30
Networking zone 3 (N3)
Hannah Carver
Short communication
Cognitive Functions in Early- Detoxified Alcohol-Dependent Inpatients and Their Association with Severity of Alcohol Dependence
15:00
to
16:30
Networking zone 3 (N3)
Prabhoo Dayal
Short communication
Efficacy of Cognitive Retraining Module for improving Cognitive Deficits of abstinent patients with Alcohol Dependence Syndrome and Opioid Dependence Syndrome in a Tertiary Care De-addiction Centre of Northern India
15:00
to
16:30
Networking zone 3 (N3)
Gauri Shanker Kaloiya
Short communication
Consumption of alcohol, tobacco and lifestyles in the population over 50 years old: Perception of quality and satisfaction with life
15:00
to
16:30
Networking zone 3 (N3)
Filipa Coelhoso
Short communication
Managed alcohol program in the low-threshold daily facility in the City of Brno, Czech Republic.
15:00
to
16:30
Networking zone 3 (N3)
Petr Blažek
Short communication
Thirty years of experience in Alcoholism treatment
15:00
to
16:30
Networking zone 3 (N3)
Inês Azevedo Silva
Oral presentation
1. What do we mean by psychiatric comorbidity or dual disorders?
15:00
to
16:30
Knowledge market 2 (K2)
Marta Torrens
Oral presentation
2. Impact of Covid19 on mental health and drug use: main findings from the EMCDDA trendspotter study
15:00
to
16:30
Knowledge market 2 (K2)
Franca Beccaria
Oral presentation
3. Psychiatric comorbidity in the European countries: prevalence and models of care
15:00
to
16:30
Knowledge market 2 (K2)
Francina Fonseca
Oral presentation
4. The dual diagnosis inpatient and outpatient treatment program in Ljubljana: practical implementatio
15:00
to
16:30
Knowledge market 2 (K2)
Nusa Segrec,
Andrej Kastelic
Discussion
Discussion: Substance use and mental health disorders in Europe
15:00
to
16:30
Knowledge market 2 (K2)
Gabriele Fischer
Oral presentation
Analysis of drugs in used syringes from sentinel European cities, 2020
15:00
to
16:30
Knowledge market 3 (K3)
Thomas Seyler
Oral presentation
The impact of opioid agonist treatment on hospitalisations for injecting-related diseases: a retrospective data linkage study
15:00
to
16:30
Knowledge market 3 (K3)
Samantha Colledge-Frisby
Oral presentation
Fear of inpatient opioid withdrawal: Addressing a modifiable barrier to health-care access for people who use illicit opioids.
15:00
to
16:30
Knowledge market 3 (K3)
Magdalena Harris
Oral presentation
1. Quality Assurance Tools: Improving Coverage, Accessibility and Quality of Drug Use Disorder Treatment
15:00
to
16:30
Knowledge market 1 (K1)
Anja Busse
Oral presentation
4. Key factors for a successful implementation of Quality Standards in Drug Demand Reduction – a Delphi Study
15:00
to
16:30
Knowledge market 1 (K1)
Rafaela Rigoni
Oral presentation
2. Further ENhancing the Implementation of Quality Standards in drug demand reduction across Europe (FENIQS-EU) project – study objectives and first realisations
15:00
to
16:30
Knowledge market 1 (K1)
Dijana Jerkovic
Oral presentation
3. State of the Art of Quality Standards implementation in drug demand reduction in Europe
15:00
to
16:30
Knowledge market 1 (K1)
Martina Feric
Oral presentation
5. An inspiring practice example of Quality Standards implementation: the Spanish Good Practice inDemand Reduction Portal (PBBPP)
15:00
to
16:30
Knowledge market 1 (K1)
Alba González-Roz
Discussion
Quality Standards in Drug Demand Reduction – lessons learned and the way forward
15:00
to
16:30
Knowledge market 1 (K1)
Wouter Vanderplasschen
Oral presentation
1. Convergences in the psychology of behavioral addictions
15:00
to
16:30
Main stage
Matthias Brand
Oral presentation
2. Convergences in the neurobiology of behavioral addictions
15:00
to
16:30
Main stage
Marc N. Potenza
Oral presentation
3. Convergences in the treatment of behavioral addictions
15:00
to
16:30
Main stage
Susana Jiménez-Murcia,
Fernando Fernández-Aranda,
Roser Granero
Oral presentation
4. Convergences in behavioral addiction policies
15:00
to
16:30
Main stage
Sophia Achab
Discussion
Convergence in behavioural addictions
15:00
to
16:30
Main stage
Luke Clark
Oral presentation
Association of opioid agonist treatment with mortality or rehospitalization following injection drug use-associated bacterial and fungal infections: linkage cohort study
15:00
to
16:30
Knowledge market 3 (K3)
Thomas Brothers
Oral presentation
0. Convergence in behavioural addictions: Introduction
15:00
to
16:30
Main stage
Zsolt Demetrovics
16:50
Oral presentation
The modelled cost-effectiveness of two psychological treatments for the reduction of alcohol consumption in alcohol-dependent individuals
16:50
to
18:20
Central square 1 (C1)
Sergio Flores
Oral presentation
Can alcohol abstinence orders reduce mortality? Insights from an individual-level analysis of 24/7 Sobriety
16:50
to
18:20
Central square 1 (C1)
Beau Kilmer
Oral presentation
Community involvement facilitating the discussion of alcohol use in primary care: A nominal group study
16:50
to
18:20
Central square 1 (C1)
Bram Pussig
Oral presentation
Modeling the Impact of a long-term horizon and multiple treatment episodes on the effectiveness and cost-effectiveness of alcohol treatment in the United States
16:50
to
18:20
Central square 1 (C1)
Carolina Barbosa
Oral presentation
Per capita alcohol consumption and alcohol-related harm: an analysis of long-term evidence from Nordic and Mediterranean countries
16:50
to
18:20
Central square 1 (C1)
Gregor Zwirn
Oral presentation
2. Impact and lessons learned in the implementation of a NBP model across the province of Quebec, Canada
16:50
to
18:20
Knowledge market 2 (K2)
Joël Tremblay
Oral presentation
1. Implementation of a substance use NBP model in a Northern Region of Ontario- results and lessons learned
16:50
to
18:20
Knowledge market 2 (K2)
Stephanie Paquette
Oral presentation
3. Development and pilot testing an integrated mental health and substance use Needs-based Planning model: Lessons learned for local planning and model refinements
16:50
to
18:20
Knowledge market 2 (K2)
Brian Rush
Oral presentation
5. Focus on implementation processes, impacts to date and pros and cons of the sustainability of the Australian Mental Health model
16:50
to
18:20
Knowledge market 2 (K2)
Sandra Diminic
Oral presentation
4. Focus on implementation processes, impacts to date and pros and cons of the sustainability of the Auralian SU model model
16:50
to
18:20
Knowledge market 2 (K2)
Alison Ritter
Oral presentation
2. Paving the Way for Improved Data Collection on Cannabis Use
16:50
to
18:20
Main stage
Susan Weiss
Oral presentation
3. The International Cannabis Toolkit (iCannToolkit): a first necessary step to integrate global multidisciplinary evidence on cannabis related risks and benefits
16:50
to
18:20
Main stage
Valentina Lorenzetti
Oral presentation
4. From standard drinks to the cannabis toolkit
16:50
to
18:20
Main stage
Antoni Gual
Oral presentation
1. The standard THC unit
16:50
to
18:20
Main stage
Tom Freeman
Oral presentation
1. The role of social work in agency processes - empirical study using the example of people who use illicit substances with a history of imprisonment
16:50
to
18:20
Networking zone 1 (N1)
Daniela Jamin
Oral presentation
2. Social work with drug users in a probation system of Kyrgyzstan
16:50
to
18:20
Networking zone 1 (N1)
Estebes uulu Tynchtyk
Oral presentation
3. Health and social welfare in prisons in the Republic of Kazakhstan – women with HIV and the role of the social worker
16:50
to
18:20
Networking zone 1 (N1)
Dalida Mukasheva
Oral presentation
Findings from treatment facility survey (EFSQ) in Lebanon’
16:50
to
18:20
Networking zone 2 (N2)
Zeinab Abbas
Oral presentation
European facility survey questioner (EFSQ) for Palestinian substance use disorder (SUD) treatment facilities.
16:50
to
18:20
Networking zone 2 (N2)
Saed Bilbeisi
Oral presentation
European treatment facility survey in Georgia
16:50
to
18:20
Networking zone 2 (N2)
Irakli Natsvlishvili
Oral presentation
Drug treatment facilities survey, Tunisia 2020
16:50
to
18:20
Networking zone 2 (N2)
Hajer Aounallah-Skhiri
Oral presentation
1. Interventions to enhance prevention of hepatitis C and HIV infection
16:50
to
18:20
Knowledge market 3 (K3)
Julie Bruneau
Oral presentation
2. Treatment as prevention for hepatitis C infection: A key piece to the elimination puzzle
16:50
to
18:20
Knowledge market 3 (K3)
Matthew Hickman
Oral presentation
3. We have reached single-diagnosis and treatment for hepatitis C infection: What next?
16:50
to
18:20
Knowledge market 3 (K3)
Jason Grebely
Oral presentation
4. Community-led initiatives to enhance prevention and treatment for hepatitis C
16:50
to
18:20
Knowledge market 3 (K3)
Judy Chang
Discussion
Strategic approach to service prioritization and resource allocation
16:50
to
18:20
Knowledge market 2 (K2)
Daniel Vigo
18:30
Discussion
Debating psychedelic-assisted treatment for substance use disorders – long overlooked or now overhyped?
18:30
to
19:30
Main stage
Tomáš Páleníček,
Andrea Jungaberle,
John Marsden,
Gabriella Gobbi
Thursday, 24 November
09:00
Keynote presentation
Addiction Recovery: From Culture to Science
09:00
to
10:30
Main stage
John F. Kelly
Keynote presentation
One should not have to recover alone
09:00
to
10:30
Main stage
Charlotte Colman
Discussion
What is next on Addiction Research? A responsible innovative approach to societal changes in Addiction
09:00
to
10:30
Knowledge market 4 (K4)
Marta Torrens,
Fernando Rodriguez De Fonseca
Oral presentation
1. Implementing patient-reported experiences (PROMs and PREMs) to improve the engagement of patients in treatment services
09:00
to
10:30
Knowledge market 4 (K4)
Joan-Ignasi Mestre-Pintó
Oral presentation
2. New challenges in drug monitoring: wastewater analysis as an alternative indicators for rapid epidemiological assessment of drug use trend
09:00
to
10:30
Knowledge market 4 (K4)
José Benito Quintana
Oral presentation
3. Promotion of health regarding the problematic drug use through interventions in educational and primary addiction treatment settings
09:00
to
10:30
Knowledge market 4 (K4)
Victor Villanueva
Oral presentation
4. Translational research as a necessary actor for fighting addiction: RIAPAd as a coordinated national cooperative framework
09:00
to
10:30
Knowledge market 4 (K4)
Fernando Rodriguez De Fonseca
Keynote presentation
Introduction to Treatment and Recovery Systems: England as a case example
09:00
to
10:30
Main stage
Ed Day
10:50
Short communication
Youth drinking in decline
10:50
to
12:20
Networking zone 3 (N3)
Johanna Loy
Short communication
Fresh Onward'. A study on group-based treatment programs for elderly with problematic alcohol use
10:50
to
12:20
Networking zone 3 (N3)
Rob Bovens
Short communication
Perceptions of family functioning in families with alcoholics in treatment
10:50
to
12:20
Networking zone 3 (N3)
Irma Kovco Vukadin
Short communication
The validity of a Screening Instrument for Intimate Partner Violence in Men with Substance Use Disorders seen in addiction specialist services.
10:50
to
12:20
Networking zone 3 (N3)
Ariadna Sanchez Codern
Short communication
The importance of social support in the treatment of alcoholism - a study from Croatia
10:50
to
12:20
Networking zone 3 (N3)
Dalibor Dolezal
Short communication
Alcohol and pregnancy – knowledge, perspetives and practice of Portuguese health professionals working with pregnant women
10:50
to
12:20
Networking zone 3 (N3)
Maria Xavier
Oral presentation
The association between moral injury and cannabis use disorder among Israeli combat veterans: current state of knowledge and future directions
10:50
to
12:20
Knowledge market 2 (K2)
Daniel Feingold
Oral presentation
Alcohol and drug use among trauma patients with injuries of violence– results from the IDART study
10:50
to
12:20
Knowledge market 2 (K2)
Benedicte Jørgenrud
Oral presentation
addictive disorders and post-traumatic stress disorders
10:50
to
12:20
Knowledge market 2 (K2)
Léa Montagnier
Oral presentation
A novel trauma-focused psychological therapy for co-occurring substance use and PTSD among adolescents
10:50
to
12:20
Knowledge market 2 (K2)
Emma Barrett
Oral presentation
Mental health and associations with tobacco smoking and quitting behaviour in the population of Germany
10:50
to
12:20
Central square 3 (C3)
Sabrina Kastaun
Oral presentation
Neuropsychology of Addictions in Therapeutic Communities: assessing and understanding cognitive recovery through a residential treatment of substance use disorders
10:50
to
12:20
Central square 3 (C3)
Simon Deniel
Oral presentation
Binge alcohol intake triggers microglial activation and TNF-dependent aberrant synaptic pruning, causing synapse loss and increased anxiety
10:50
to
12:20
Central square 3 (C3)
Teresa Summavielle
Oral presentation
High dose anabolic steroid use and facial emotion recognition, the hormonal influence on social cognition.
10:50
to
12:20
Central square 3 (C3)
Astrid Bjørnebekk
Discussion
Challenges faced, political will, societal willingness and community approach of the harm reduction policy.
10:50
to
12:20
Knowledge market 4 (K4)
Athanasios Theocharis
Short communication
Gender differences in cannabis use disorder symptoms: A network analysis
10:50
to
12:20
Networking zone 4 (N4)
Emese Kroon
Short communication
Photovoicing interconnected sources of recovery capital of women with a drug use history
10:50
to
12:20
Networking zone 4 (N4)
Jessica De Maeyer
Short communication
Complex social and health care needs of women who seek addiction treatment: listening to their voices to guide long-term integrated services that take into account gender
10:50
to
12:20
Networking zone 4 (N4)
Karine Bertrand
Short communication
Mutual help groups for women who use drugs, as a community-led gender sensitive harm reduction response
10:50
to
12:20
Networking zone 4 (N4)
Lígia Parodi
Oral presentation
1. Steps forward in an attempt of OKANA to widen harm reduction to risk reduction: entries and facilities within a new concept based on the real needs
10:50
to
12:20
Knowledge market 4 (K4)
Athanasios Theocharis
Oral presentation
2. Streetwork and Outreach Networking
10:50
to
12:20
Knowledge market 4 (K4)
Lagakou Litsa
Oral presentation
3. Direct access to OST treatment and integrated therapy: Lessons learned from streets to community
10:50
to
12:20
Knowledge market 4 (K4)
Nikos Avgerinos
Oral presentation
4. Harm Reduction and Covid 19: Hostel 'IONIS', an example of a holistic intervention for homeless drug users
10:50
to
12:20
Knowledge market 4 (K4)
Foteini Leobilla
Short communication
Exploring intersections between gender and drug use in East and Southern Africa
10:50
to
12:20
Networking zone 4 (N4)
Charity Monareng
Short communication
Mutual support groups among women who use drugs in a community context as a comprehensive and affordable strategy to reduce inequalities
10:50
to
12:20
Networking zone 4 (N4)
Joana Canedo
13:20
Short communication
SHIFT + Parent Training - An Intervention for Mothers and Fathers Using Illicit Drugs'
13:20
to
14:50
Networking zone 4 (N4)
Diana Moesgen
Short communication
Perceptions of prospective pharmaceutical stimulant substitution treatments among people who use illicit stimulants in Vancouver, Canada
13:20
to
14:50
Networking zone 4 (N4)
Taylor Fleming
Short communication
Trends and factors associated with illicit drug use and HIV outcomes in South Africa: findings from multiple national population-based household surveys
13:20
to
14:50
Networking zone 4 (N4)
Kennedy Kipkoech
Short communication
Perceived Impact of Storytelling on Substance Use Self-Stigma
13:20
to
14:50
Networking zone 4 (N4)
Glenn Sterner
Short communication
Social attitudes towards drug users in the context of perceptions of other marginalised social groups, based on the NSAPH 2019 Survey
13:20
to
14:50
Networking zone 4 (N4)
Katalin Felvinczi
Short communication
Cannabis engagement in Riga, Latvia: Voices from impacted communities
13:20
to
14:50
Networking zone 4 (N4)
Kristiana Bebre
Oral presentation
Drinking with Coworkers – How to Make it a Safe and Including Event
13:20
to
14:50
Central square 1 (C1)
Stian Fjerdingen
Oral presentation
Accuracy, acceptability, and feasibility of transdermal alcohol sensors: Two systematic reviews
13:20
to
14:50
Central square 1 (C1)
Eileen Brobbin
Oral presentation
Perceived barriers and facilitators to accessing effective clinical supervision and the implementation of a clinical supervision exchange model in the alcohol and other drug sector
13:20
to
14:50
Central square 1 (C1)
Courtney O'Donnell
Oral presentation
Using technology to digitally disrupt the delivery of outcome measures in Alcohol and Other Drug (AOD) services
13:20
to
14:50
Central square 1 (C1)
Leanne Hides
Oral presentation
Declining Prevalence of Current HCV Infection and Increased Treatment Uptake Among People Who Inject Drugs: The ETHOS Engage Study
13:20
to
14:50
Knowledge market 3 (K3)
Anna Conway
Oral presentation
Non-uptake of treatment for hepatitis C in the antiviral era: A qualitative analysis
13:20
to
14:50
Knowledge market 3 (K3)
Suzanne Fraser
Oral presentation
Simplified HCV management algorithm for methadone clinics: a pilot study in Ukraine
13:20
to
14:50
Knowledge market 3 (K3)
Kostyantyn Dumchev
Oral presentation
A novel hepatitis C intervention in Denmark to test and treat people who inject drugs
13:20
to
14:50
Knowledge market 3 (K3)
Jonas Demant
e-poster
The availability of offline gambling premises in Catalonia and its relationship with socioeconomic determinants
13:20
to
14:50
Networking zone 1 (N1)
Susanna Puigcorbé Alcalà
e-poster
Emotion regulation-enhanced group treatment for gambling disorder: a non- randomized pilot trial
13:20
to
14:50
Networking zone 1 (N1)
Viktor Månsson
e-poster
Gambling and social background in cases of suicide
13:20
to
14:50
Networking zone 1 (N1)
Kalle Lind
e-poster
Experiencing COVID-19 as gamblers: Availability restrictions, services, and habits
13:20
to
14:50
Networking zone 1 (N1)
Virve Marionneau
e-poster
Social media addiction and mental health among Algerian university students during the Covid-19 pandemic
13:20
to
14:50
Networking zone 1 (N1)
Nadia Sam
e-poster
Emerging adults 'in game': Research project on how Individual and family variables influence behaviors and motivations related to video games
13:20
to
14:50
Networking zone 1 (N1)
Susana Costa
e-poster
Screen Time and Mental Health in Algerian Population During the First Wave of the COVID-19 Pandemic
13:20
to
14:50
Networking zone 1 (N1)
Slimane Djillali
e-poster
Changing patterns in online addictive behaviours during COVID-19 pandemic
13:20
to
14:50
Networking zone 1 (N1)
João Castro Rodrigues
e-poster
Addictive behaviours among first year high education students – a descriptive study
13:20
to
14:50
Networking zone 1 (N1)
Gizela Cardoso
e-poster
Watching TV Series Motives (WTSMQ) y Binge-watching Engagement and Symptoms (BWESQ): Psychometric properties in Peruvian adults
13:20
to
14:50
Networking zone 1 (N1)
Fiorella Otiniano Campos
Oral presentation
What will the future nicotine market look like in a post-smoking era?
13:20
to
14:50
Central square 3 (C3)
Karl Erik Lund
Oral presentation
Effectiveness of e-cigarettes for smoking cessation in the German population - a comparison with nicotine replacement therapy and no use of evidence-based support (DEBRA study)
13:20
to
14:50
Central square 3 (C3)
Daniel Kotz
Oral presentation
The lifetime costs and benefits of subsidizing the cost of nicotine replacement therapy in Sweden
13:20
to
14:50
Central square 3 (C3)
Inna Feldman
Oral presentation
Cessation of Smoking Trial in the Emergency Department- interim results
13:20
to
14:50
Central square 3 (C3)
Ian Pope
Oral presentation
Motivation to stop smoking in the German population: recent trends and associated factors (DEBRA study)
13:20
to
14:50
Central square 3 (C3)
Benjamin Borchardt
Short communication
Evaluating Cracks in the Ice – a digital health initiative to support families, health workers and communities affected by crystal methamphetamine (‘ice’)
13:20
to
14:50
Networking zone 3 (N3)
Steph Kershaw
Short communication
Exclusive therapeutic use of cannabis in France: characteristics and use patterns in a large sample of daily users
13:20
to
14:50
Networking zone 3 (N3)
Martin Bastien
Short communication
Psychoactive substance use among Serbian adults – results from online survey
13:20
to
14:50
Networking zone 3 (N3)
Biljana Kilibarda
Short communication
Harm Reduction for Chemsex in Lisbon: community-based interventions for a hard-to-reach group, during the COVID-19 pandemic
13:20
to
14:50
Networking zone 3 (N3)
Filipe Couto Gomes
Short communication
Z-Drugs Dependence: An Awakening Truth
13:20
to
14:50
Networking zone 3 (N3)
Afonso Homem De Matos
Short communication
Under-reporting of meth/amphetamine use in Australia following negative media coverage
13:20
to
14:50
Networking zone 4 (N4)
Daniel Stjepanovic
Short communication
The epigenetic effects of cannabis exposure and their link to behavior and emotional manifestations – a scoping review
13:20
to
14:50
Networking zone 3 (N3)
Ana Sofia Machado
Short communication
Treatment of drug use disorders in Central Asia, China, and Germany – what is the state of the art?
13:20
to
14:50
Networking zone 4 (N4)
Ingo Ilja Michels
15:00
Short communication
Effectiveness of regulatory policies on online/digital/internet – mediated alcohol marketing: a systematic review
15:00
to
16:30
Networking zone 3 (N3)
Sandra Rados Krnel
Short communication
Outcomes of a health economic evaluation of digital alcohol and tobacco interventions for cancer survivors alongside randomized controlled trials
15:00
to
16:30
Networking zone 3 (N3)
Matthijs Blankers
Short communication
Impact of digital alcohol marketing on alcohol-related attitudes and alcohol consumption
15:00
to
16:30
Networking zone 3 (N3)
Wim Van Dalen
Short communication
Benefits and Challenges of Integrating Yoga in Government-Funded Substance Addiction Treatment Programs in India: Results from a Mixed Methods Research Study with Exploratory Sequential Design.
15:00
to
16:30
Networking zone 3 (N3)
Sebastian Perumbilly,
Jake Zoubek,
Aubrey Grodin
Short communication
The global burden of alcohol use disorders: methodological considerations
15:00
to
16:30
Networking zone 3 (N3)
Laura Jones
Short communication
Structured Leisure Activities (SLA) and Adolescent Alcohol Use
15:00
to
16:30
Networking zone 3 (N3)
Matea Belošević
Short communication
Social networks amongst people with alcohol dependence who frequently attend hospital: an exploratory qualitative study
15:00
to
16:30
Networking zone 3 (N3)
Stephanie Fincham-Campbell
Short communication
Alcohol and other drug use and treatment for Aboriginal Australians involved in the criminal justice system
15:00
to
16:30
Networking zone 3 (N3)
Michael Doyle
Oral presentation
The social, material and temporal effects of extended-release buprenorphine depot treatment for opioid dependence: an Australian qualitative study
15:00
to
16:30
Knowledge market 3 (K3)
Kari Lancaster
Oral presentation
Peer-led community based infectious disease integrated testing and linkage to care in inclusion health populations in London, UK
15:00
to
16:30
Knowledge market 3 (K3)
Julian Surey
Short communication
Transactional sex as a pathway for rising sexually transmitted infections amidst the opioid epidemic in the United States
15:00
to
16:30
Networking zone 4 (N4)
Mance Buttram
Short communication
Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, Switzerland
15:00
to
16:30
Networking zone 4 (N4)
Claudia Bernardini
Short communication
Individual and structural factors associated with recent hepatitis C testing in people who inject drugs: gender-based analyses of the Cosinus Cohort
15:00
to
16:30
Networking zone 4 (N4)
Ilhame Anwar
Short communication
Real-world hepatitis C treatment outcomes among people who inject drugs at the Stockholm needle exchange program, Sweden
15:00
to
16:30
Networking zone 4 (N4)
Martin Kåberg
Short communication
Educations for safer injection in the Mobile Drug Consumption Room in Lisbon
15:00
to
16:30
Networking zone 4 (N4)
Ângela Leite
Short communication
Real time surveillance on the impact of restrictions on harm reduction services to improve responsiveness and reduce harms in unprecedented times
15:00
to
16:30
Networking zone 4 (N4)
Josie Smith
Short communication
Integrating hepatitis C treatment in methadone clinic in Ukraine: perspectives of participants and providers.
15:00
to
16:30
Networking zone 4 (N4)
Tetiana Kiriazova
Short communication
Harm reduction services in the Netherlands: recent developments and challenges.
15:00
to
16:30
Networking zone 4 (N4)
Nadine G.M. van Gelder
Oral presentation
Serious non-fatal and fatal opioid overdose events in a cohort of hospital patients seen by an addiction consultation service: Secondary analysis of the NavSTAR trial.
15:00
to
16:30
Knowledge market 3 (K3)
Jan Gryczynski
Oral presentation
Screening, diagnosis and treatment of infectious diseases with at-risk populations: 20 years of data from a harm reduction program managed by Ares do Pinhal in Lisbon
15:00
to
16:30
Knowledge market 3 (K3)
Filipa Barata
Oral presentation
2. Drug-related deaths in prisons in England and Wales, 2015-2020: an examination of key trends and issues for policy and practice
15:00
to
16:30
Knowledge market 1 (K1)
Karen Duke
Oral presentation
3. The role of Primary Care in the prevention of drug-related deaths: Patient and family member perspectives
15:00
to
16:30
Knowledge market 1 (K1)
Katie Colliver
Discussion
What can a social, structural and systems analysis tell us about drug-related deaths and what are the implications for policy and addiction science?
15:00
to
16:30
Knowledge market 1 (K1)
Anne Whittaker
Oral presentation
4. The role of Primary Care in the prevention of drug-related deaths: service provider perspectives
15:00
to
16:30
Knowledge market 1 (K1)
Betsy Thom
Oral presentation
5. Drug Policy and The Rise and Decline of Racial Stratification of Prescribing and Overdose Mortality
15:00
to
16:30
Knowledge market 1 (K1)
Brian Kelly
Oral presentation
1. Drug-related deaths among young people: a social, structural and systems autopsy
15:00
to
16:30
Knowledge market 1 (K1)
Aileen O'Gorman
Oral presentation
1. Combining Psychedelic Treatments with Current Substance Use Disorder Treatments
15:00
to
16:30
Main stage
Johannes Thrul
Oral presentation
2. Improving the self: Psychedelic drug use and the enhancement-treatment debate
15:00
to
16:30
Main stage
Margit Anne Petersen
Oral presentation
3. Psychedelics in psychiatry: focus on evidence and mechanisms of relevance to affective disorders and addictions
15:00
to
16:30
Main stage
David Erritzoe
e-poster
The Impact of Institutions for Mental Diseases (IMD) Exclusion Waivers on the Change in Availability of Mental and Addiction Treatment
15:00
to
16:30
Networking zone 1 (N1)
Yimin Ge
e-poster
Real-world effectiveness of various pharmacological treatments in methamphetamine/amphetamine use disorders
15:00
to
16:30
Networking zone 1 (N1)
Milja Heikkinen
e-poster
Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up
15:00
to
16:30
Networking zone 1 (N1)
Zhanna Gaulen
e-poster
Starting Buprenorphine therapy. Challenges and difficulties
15:00
to
16:30
Networking zone 1 (N1)
Esmeralda Thoma
e-poster
Psychostimulant-induced neuroinflammation: the protective role of IL-10
15:00
to
16:30
Networking zone 1 (N1)
Ana Isabel Silva
e-poster
Characterising the neurobiology of detoxification in opiate dependence: is there a role for NK1 antagonism to improve outcomes?
15:00
to
16:30
Networking zone 1 (N1)
Katherine Herlinger
e-poster
Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical Trial
15:00
to
16:30
Networking zone 1 (N1)
Arild Opheim
Oral presentation
2. Results of the literature review and the Delphi expert consensus finding process on Methamphetamine Prevention Interventions
15:00
to
16:30
Knowledge market 4 (K4)
Benjamin Petruželka
Oral presentation
4. The RE-AIM framework for evaluating implementation processes and public health impact
15:00
to
16:30
Knowledge market 4 (K4)
Harald Lahusen
e-poster
Outcome measurement and evaluation as a routine practice in alcohol and other drug services in Belgium (OMER-BE)
15:00
to
16:30
Networking zone 1 (N1)
Amine Zerrouk
e-poster
Medically supervised opioid withdrawal treatment: is it possible to predict the successful outcome?
15:00
to
16:30
Networking zone 1 (N1)
Artūras Barkus
e-poster
Patient-reported outcomes of subcutaneous depot buprenorphine treatment in Australian correctional centres
15:00
to
16:30
Networking zone 1 (N1)
Nadine Ezard
Oral presentation
3. Development of tailored prevention intervention packages
15:00
to
16:30
Knowledge market 4 (K4)
Magdalena Rowicka
Oral presentation
1. Aims, scope and methodology of IMPRESA
15:00
to
16:30
Knowledge market 4 (K4)
Dovilė Mačiulytė
16:50
Oral presentation
1. Drug Market and Use Changes During the COVID-19 Pandemic: A Global Survey
16:50
to
18:20
Insights zone 4 (I4)
Alexander Baldacchino
Oral presentation
2. Cognitive Training and Rehabilitation Approaches for Addiction: A Delphi Consensus
16:50
to
18:20
Insights zone 4 (I4)
Hamed Ekhtiari
Oral presentation
3. A Methodological Checklist for fMRI Cue Reactivity Studies in Addictions: Development and Expert Consensus
16:50
to
18:20
Insights zone 4 (I4)
Antonio Verdejo-Garcia
Oral presentation
4. Translating Neuroscience into Addiction Prevention: A Delphi Consensus Study
16:50
to
18:20
Insights zone 4 (I4)
Tara Rezapour
Oral presentation
5. Global Experts-centered Consensus Development; A Series of Methodologies for Extending Harmonization and Global Representativeness in Addiction Science
16:50
to
18:20
Insights zone 4 (I4)
Arash Khojasteh Zonoozi
Discussion
How to Expand Expert-centered Methodologies within Various Areas of Addiction Science in a Global Level? A Discussion on First-hand Experiences in the Field and the Opportunities and Challenges on the Road Ahead
16:50
to
18:20
Insights zone 4 (I4)
Hamed Ekhtiari,
Marc N. Potenza
Oral presentation
The acceptability and feasibility of implementing and evaluating the Parents under Pressure (PuP) parenting programme with opioid-dependent fathers and their families: results from the PuP4Dads study.
16:50
to
18:20
Central square 3 (C3)
Anne Whittaker
Oral presentation
1. A predictive processing account of problem gambling
16:50
to
18:20
Insights zone 3 (I3)
Jarno Tuominen
Oral presentation
2. Flow in (problem) gambling
16:50
to
18:20
Insights zone 3 (I3)
Valtteri Arstila
Oral presentation
3. The ethical implications of how problem gambling is conceptualized
16:50
to
18:20
Insights zone 3 (I3)
Susanne Uusitalo
Short communication
A Feasibility Study of Mentalization Based Therapy for Antisocial personality disorder with substance use disorder in Norway- preliminary findings
16:50
to
18:20
Networking zone 3 (N3)
Katharina Morken
Oral presentation
Ayahuasca-assisted addiction treatment in Peru: qualitative results from a multi-year, mixed-methods study
16:50
to
18:20
Central square 3 (C3)
Olivia Marcus
Short communication
Working in drug treatment and health care facilities
16:50
to
18:20
Networking zone 3 (N3)
Maitena Milhet
Oral presentation
EXtended-release Pharmacotherapy for Opioid Use Disorder (EXPO)
16:50
to
18:20
Central square 3 (C3)
John Marsden
Short communication
Incidence and determinants of CoVID-19 in patients seeking treatment of Substance Use Disorder: a population-based linkage study
16:50
to
18:20
Networking zone 3 (N3)
Irene Lana
Oral presentation
Characteristics of concerned persons (CPs) accessing treatment services in their own right: A secondary analysis of Irish health data for 2010-2020.
16:50
to
18:20
Central square 3 (C3)
Cathy Kelleher
Oral presentation
1. Assisting drug policies in the quest for an evidence-base: challenges related to the development of a National Action Plan for the Drug Information System
16:50
to
18:20
Networking zone 2 (N2)
Viktor Mravcik
Short communication
Perspectives Pathways and Priorities of People with Lived and Living Experience of Substance Use: Informing Policies (P5 Project YXE)
16:50
to
18:20
Networking zone 3 (N3)
Barbara Fornssler
Oral presentation
2. Shared responsibilities among different stakeholders in the quest for evidence: experiences from Georgia
16:50
to
18:20
Networking zone 2 (N2)
Ketevan Sarajishvili
Short communication
The Treatment of Addictions in Portugal - What Future?
16:50
to
18:20
Networking zone 3 (N3)
João Feliz
Oral presentation
6. European Prevention Curriculum – a tool for disseminating effective modern prevention approaches and facilitating well-informed choices about funding and implementation priorities: reflections from Georgia
16:50
to
18:20
Networking zone 2 (N2)
Jana D. Javakhishvili
Short communication
The effect of opioid agonist therapy on mental health of PWID in Ukraine
16:50
to
18:20
Networking zone 3 (N3)
Iryna Ivanchuk
Oral presentation
3. Capacity building for practitioners on evidence-based drug treatment interventions aligned with EU quality standards and tailored to national needs
16:50
to
18:20
Networking zone 2 (N2)
Anna Tarján
Oral presentation
1. Pharmacological treatments for cannabis use disorder
16:50
to
18:20
Knowledge market 4 (K4)
Albert Batalla
Oral presentation
4. Capacity building for practitioners on evidence-based drug treatment interventions aligned with EU quality standards and tailored to national needs: reflections from Georgia
16:50
to
18:20
Networking zone 2 (N2)
David Otiashvili
Oral presentation
2. Motivational Interviewing for CUD: current situation and gaps
16:50
to
18:20
Knowledge market 4 (K4)
Hugo López Pelayo
Oral presentation
5. The importance of an evidence-based approach in the development of a national drug policy
16:50
to
18:20
Networking zone 2 (N2)
Artur Malczewski
Oral presentation
3. Cultural and language adaptation to Spanish of CANnabis DISorder Program (CANDIS)
16:50
to
18:20
Knowledge market 4 (K4)
Pablo Guzmán
Discussion
European Prevention Curriculum
16:50
to
18:20
Networking zone 2 (N2)
Gregor Burkhart
Oral presentation
4. Pros and Cons of Group Therapy for Cannabis Use Disorders: Is it an opportunity for cultural adaptation?
16:50
to
18:20
Knowledge market 4 (K4)
Mercè Balcells
Short communication
Outreach for socially marginalized trimorbid veterans in Denmark – preliminary results
16:50
to
18:20
Networking zone 3 (N3)
Henrik Thiesen
18:30
Oral presentation
Progress towards elimination of hepatitis C among people who inject drugs in Norway
18:30
to
19:30
Knowledge market 4 (K4)
Knut Boe Kielland
Oral presentation
2. HCV treatment uptake among marginalized people who inject drugs in Norway: A registry-based study
18:30
to
19:30
Knowledge market 4 (K4)
Linda Wüsthoff
Oral presentation
3. HCV treatment uptake among marginalized people who inject drugs in Norway: A registry-based study, and the Progress towards elimination of hepatitis C among people who inject drugs in Norway
18:30
to
19:30
Knowledge market 4 (K4)
Knut Boe Kielland
Oral presentation
2. Opportunistic Treatment of Hepatitis C Virus Infection: A pragmatic stepped-wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs (OPPORTUNI-C)
18:30
to
19:30
Knowledge market 4 (K4)
Olav Dalgard
Oral presentation
Opportunistic Treatment of Hepatitis C Virus Infection: A pragmatic stepped-wedge clusterrandomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs (OPPORTUNI-C)
18:30
to
19:30
Knowledge market 4 (K4)
Havard Midgard
Oral presentation
1. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program. And new models to reach those hard to reach; results from Point of Care testing and treatment in a nurse led and a peer led mobile clinic
18:30
to
19:30
Knowledge market 4 (K4)
Linda Wüsthoff
Discussion
Debating addiction, compulsive behaviours and unhealthy habits - A common aetiology and implications for practice?
18:30
to
19:30
Main stage
Zsolt Demetrovics,
Sophia Achab,
Wim van den Brink,
Fernando Fernández-Aranda
Friday, 25 November
09:00
Oral presentation
Treatment Seeking Pattern of Relapse Cases of Substance Use Disorder in Bangladesh
09:00
to
10:30
Central square 2 (C2)
Iqbal Masud
Oral presentation
Recovery and substitute addictions
09:00
to
10:30
Central square 2 (C2)
Deborah Louise Sinclair
Oral presentation
Determinants of recovery capital among persons in early and stable recovery from drug addiction
09:00
to
10:30
Central square 2 (C2)
Wouter Vanderplasschen
Oral presentation
An exploratory analysis of actigraphy and sleep diaries in a methamphetamine withdrawal clinical trial
09:00
to
10:30
Central square 2 (C2)
Liam Acheson
10:50
Oral presentation
2. A rapid assessment of take-home naloxone provision during COVID-19 in Europe
10:50
to
12:20
Insights zone 4 (I4)
Rebecca Mc Donald
Oral presentation
3. Will they accept the vaccine? A 2021 COVID-19 survey among 477 people who use drugs in Norway
10:50
to
12:20
Insights zone 4 (I4)
Gabrielle K. Welle-Strand
Oral presentation
1. Revised service delivery of opioid agonist treatment in Norway in 2021, the second year of the pandemic: a national cross-sectional study of treatment provider experiences
10:50
to
12:20
Insights zone 4 (I4)
Anne Berit Bech
Oral presentation
4. Have predictors of drug addiction relapse changed during the COVID-19 pandemic? A prospective study of recovery pathways in the Netherlands, Belgium and UK
10:50
to
12:20
Insights zone 4 (I4)
Thomas Martinelli
Oral presentation
5. The impacts of COVID-19 pandemic on drug purchasing behaviours of people who use methamphetamine in Victoria, Melbourne.
10:50
to
12:20
Insights zone 4 (I4)
Kasun Rathnayake
Oral presentation
Optimising digital tools for substance use and substance use disorders by 2030: a backcasting exercise
10:50
to
12:20
Insights zone 1 (I1)
Elsa Caballeria,
AbuTaher AbuTaher,
Florian Scheibein
13:20
Oral presentation
1. Provision of harm reduction interventions in European prisons: short overview of available services
13:20
to
14:50
Main stage
Linda Montanari
Oral presentation
2. Hepatitis C and HIV associated risk factors among people in prison in Latvia, Lithuania, Portugal, Spain: informing interventions to prevent communicable diseases in prison setting
13:20
to
14:50
Main stage
Laura Isajeva
Oral presentation
3. The international guidance on harm reduction interventions in prisons
13:20
to
14:50
Main stage
Ehab Salah
Oral presentation
5. Harm reduction interventions and viral hepatitis elimination in prison: models of care and barriers for implementation
13:20
to
14:50
Main stage
Lara Tavoschi
Oral presentation
4. Impact, role, and prevalence of medication assisted treatment (MAT) for opioid users in European prisons
13:20
to
14:50
Main stage
Heino Stöver
Oral presentation
Prevention and Treatment of hazardous Substance Use among Refugees: Perspectives from Germany
13:20
to
14:50
Central square 3 (C3)
Marion Laging
Oral presentation
Psychosocial functions of drug using and selling among young persons in Malmö who came to Sweden as unaccompanied refugee minors
13:20
to
14:50
Central square 3 (C3)
Anke Stallwitz
Oral presentation
Re-visioning from risk and safety to survival and wellness; behaviours among people who use methamphetamine with opioids in British Columbia, Canada
13:20
to
14:50
Central square 3 (C3)
Jessica Xavier
Oral presentation
Indigenous Peoples experiences with overdose and response in Vancouver, Canada's Downtown Eastside
13:20
to
14:50
Central square 3 (C3)
Jennifer Lavalley
Oral presentation
Watch out for the boogieman': multiple stigma and recovery experiences of ethnic minorities with substance use problems
13:20
to
14:50
Central square 3 (C3)
Aline Pouille
Discussion
Lessons for future clinical research trials and clinical practice
13:20
to
14:50
Networking zone 3 (N3)
Karl Mann
Oral presentation
1. A novel way of enhancing adherence to acamprosate for alcohol dependence: The Alcohol Dependence and Adherence to Medicine (ADAM) trial
13:20
to
14:50
Networking zone 3 (N3)
Thomas Phillips
Oral presentation
2. Effectiveness and cost-effectiveness of face-to-face and electronic brief interventions versus screening alone to reduce alcohol consumption among high-risk adolescents presenting to Emergency Departments: three-arm pragmatic randomised trial
13:20
to
14:50
Networking zone 3 (N3)
Paolo Deluca
Oral presentation
3. Alcohol Assertive Outreach Treatment randomised controlled trial: a mixed methods economic evaluation
13:20
to
14:50
Networking zone 3 (N3)
Amy Wolstenholme
Discussion
Prison health in Europe
13:20
to
14:50
Main stage
Fadi Meroueh,
Filipa Alves da Costa
15:30
Keynote presentation
Providing care in a time of war — perspectives from Ukraine
15:30
to
16:00
Main stage
Irina Pinchuk